SSc-ILD Patients on Ofev See Twofold Lung Decline Over Healthy Matches
People treated with Ofev (nintedanib) for interstitial lung disease associated with systemic sclerosis (SSc-ILD) had a twofold loss of lung function over one year compared to a hypothetical group of matched healthy references whose lung function declines naturally with age, an analysis of the SENSCIS trial showed. The…